Literature DB >> 18756809

[Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures].

R A Khamitov, S Ia Loginova, V N Shchukina, S V Borisevich, V A Maksimov, A M Shuster.   

Abstract

Experimental studies of arbidol and arbidol mesylate versus ribavirin suggest that insertion of these agents into the nutrient medium of the cultured cells GMK-AH-1 (D) after infection at concentrations of 50, 25, and 100 microg/ml, respectively, is effective in suppressing the reproduction of severe acute respiratory syndrome (SARS) virus. Arbidol and arbidol mesylate were shown to have a direct antiviral effect in early viral replication in the cultured cells. The promising antiviral agent is arbidol mesylate that is nearly 5 times as effective as arbidol in reducing the reproduction of SARS virus in the cultured cells. Insertion of arbidol, arbidol mesylate, and ribavirin into the nutrient medium 2 hours after infection of porcine embryonic renal cells caused a reduction in the accumulation of the pathogen by 2.5, 2.1, and 2.6 Ig, respectively.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18756809

Source DB:  PubMed          Journal:  Vopr Virusol        ISSN: 0507-4088


  73 in total

1.  Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.

Authors:  Wei Liu; Pengxiang Zhou; Ken Chen; Zhikang Ye; Fang Liu; Xiaotong Li; Na He; Ziyang Wu; Qi Zhang; Xuepeng Gong; Qiyu Tang; Xin Du; Yingqiu Ying; Xiaohan Xu; Yahui Zhang; Jinyu Liu; Yun Li; Ning Shen; Rachel J Couban; Quazi I Ibrahim; Gordon Guyatt; Suodi Zhai
Journal:  CMAJ       Date:  2020-06-03       Impact factor: 8.262

2.  Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy.

Authors:  Dale L Barnard; Yohichi Kumaki
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

Review 3.  Immune-based therapeutic approaches in COVID-19.

Authors:  Aysan Moeinafshar; Niloufar Yazdanpanah; Nima Rezaei
Journal:  Biomed Pharmacother       Date:  2022-05-16       Impact factor: 7.419

Review 4.  Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19.

Authors:  Mark Laws; Yasmin M Surani; Md Mahbub Hasan; Yiyuan Chen; Peiqin Jin; Taha Al-Adhami; Madiha Chowdhury; Aqeel Imran; Ioannis Psaltis; Shirin Jamshidi; Kazi S Nahar; Khondaker Miraz Rahman
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

5. 

Authors:  Wei Liu; Pengxiang Zhou; Ken Chen; Zhikang Ye; Fang Liu; Xiaotong Li; Na He; Ziyang Wu; Qi Zhang; Xuepeng Gong; Qiyu Tang; Xin Du; Yingqiu Ying; Xiaohan Xu; Yahui Zhang; Jinyu Liu; Yun Li; Ning Shen; Rachel J Couban; Quazi I Ibrahim; Gordon Guyatt; Suodi Zhai
Journal:  CMAJ       Date:  2020-11-23       Impact factor: 8.262

Review 6.  COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development.

Authors:  Manasi P Jogalekar; Anurag Veerabathini; Ankit B Patel
Journal:  Exp Biol Med (Maywood)       Date:  2021-03-23

Review 7.  Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review.

Authors:  Duygu Ağagündüz; Menşure Nur Çelik; Merve Esra Çıtar Dazıroğlu; Raffaele Capasso
Journal:  Nutrients       Date:  2021-05-04       Impact factor: 5.717

Review 8.  COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern.

Authors:  Md Zeyaullah; Abdullah M AlShahrani; Khursheed Muzammil; Irfan Ahmad; Shane Alam; Wajihul Hasan Khan; Razi Ahmad
Journal:  Front Genet       Date:  2021-06-15       Impact factor: 4.599

Review 9.  Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.

Authors:  Ilad Alavi Darazam; Shervin Shokouhi; Masoud Mardani; Mohamad Amin Pourhoseingholi; Mohammad Mahdi Rabiei; Firouze Hatami; Minoosh Shabani; Omid Moradi; Farid Javandoust Gharehbagh; Seyed Sina Naghibi Irvani; Mahdi Amirdosara; Mohammadreza Hajiesmaeili; Omidvar Rezaei; Ali Khoshkar; Legha Lotfollahi; Latif Gachkar; Hadiseh Shabanpour Dehbsneh; Negar Khalili; Azam Soleymaninia; Akram Hoseyni Kusha; Maryam Taleb Shoushtari; Parham Torabinavid
Journal:  Int Immunopharmacol       Date:  2021-07-10       Impact factor: 4.932

Review 10.  A global treatments for coronaviruses including COVID-19.

Authors:  Bahman Yousefi; Saeid Valizadeh; Hadi Ghaffari; Azadeh Vahedi; Mohsen Karbalaei; Majid Eslami
Journal:  J Cell Physiol       Date:  2020-05-11       Impact factor: 6.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.